Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552708 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
A Phase 1 study of Hypertension, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00552708: Completed Phase 1 study of Hypertension, sponsored by GlaxoSmithKline.
NCT00552708 is a Phase 1 study of Hypertension that has completed, run by GlaxoSmithKline. The registered enrollment target is 55 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00552708, a Phase 1 study of Hypertension, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a randomized study investigating the bioequivalence of COREG CR to its components, COREG and Lisinopril (ZESTRIL). PK samples will be obtained throughout the study to investigate the PK of COREG CR FDC to COREG and Lisinopril
Conditions Studied
Interventions
- DRUG Lisinopril
- DRUG COREG CR
Study Locations (1)
Washington
- GSK Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
What the finished NCT00552708 record still lists
NCT00552708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Lisinopril is the first listed.
NCT00552708 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00552708 about?
NCT00552708 is a clinical study titled "A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.". This study will be a randomized study investigating the bioequivalence of COREG CR to its components, COREG and Lisinopril (ZESTRIL). PK samples will be obtained throughout the study to investigate the PK of COREG CR FDC to COREG and Lisinopril
What is the current status of trial NCT00552708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2007-09. Estimated completion is 2007-12.
What conditions does trial NCT00552708 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00552708?
The interventions under investigation include: Lisinopril (DRUG), COREG CR (DRUG).
Who is sponsoring clinical trial NCT00552708?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00552708 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00552708's enrollment target sits among peer trials
55 360th of 470 higher than 109 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Sympathetic Mechanisms in Obesity-Crossover Design
RECRUITING · Phase 1
-
Targeting Endoplasmic Reticulum Stress in Human Hypertension
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia